Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128961 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL128669 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL128196 | 1.00 | — | — | |
| SCHEMBL1274555 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1275460 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL128011 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL141691 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL1228396 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL20503206 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL20503190 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000070-B1 | SILICON-CONTAINING CHAIN EXTENDERS | AORTECH BIOMATERIALS PTY LTD (AU) | 2003-09-10 | — | — | EP | claimed |
| EP-0984997-B1 | SILICON-BASED POLYCARBONATES | AORTECH BIOMATERIALS PTY LTD (AU) | 2002-09-18 | — | — | EP | claimed |
| US-6420452-B1 | POLYURETHANES WITH EXTENDERS | AORTECH BIOMATERIALS PTY LTD (AU) | 2002-07-16 | — | — | US | claimed |
| EP-1000070-A4 | SILICON-CONTAINING CHAIN EXTENDERS | CARDIAC CRC NOMINEES PTY LTD (AU) | 2000-06-07 | — | — | EP | claimed |
| EP-1000070-A1 | SILICON-CONTAINING CHAIN EXTENDERS | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 2000-05-17 | — | — | EP | claimed |
| EP-0984997-A4 | SILICON-BASED POLYCARBONATES | CARDIAC CRC NOMINEES PTY LTD (AU) | 2000-03-29 | — | — | EP | claimed |
| EP-0984997-A1 | SILICON-BASED POLYCARBONATES | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 2000-03-15 | — | — | EP | claimed |
| WO-1999003863-A1 | SILICON-CONTAINING CHAIN EXTENDERS | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1999-01-28 | — | — | WO | claimed |
| WO-1998054242-A1 | SILICON-BASED POLYCARBONATES | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1998-12-03 | — | — | WO | claimed |
| US-20240218254-A1 | ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME | MIYOSHI OIL & FAT CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| EP-4327889-A1 | FORMULATION USING AMINO ACID AND CARBOXYLIC ACID, ORGANIC SALT, AND COMPOSITION COMPRISING SAME AND USE THEREOF | Miyoshi Oil & Fat Co., Ltd. (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-114106278-B | Polyurethane/urea materials | 联邦科学和工业研究组织 | 2024-01-12 | — | — | CN | disclosed |
| CN-117203302-A | Complexes, organic salts and compositions containing them and uses thereof | 三吉油脂株式会社 | 2023-12-08 | — | — | CN | disclosed |
| CN-117203308-A | Additive for making interface active and emulsifying composition using the same | 三吉油脂株式会社 | 2023-12-08 | — | — | CN | disclosed |
| US-5200412-A | Antiinflammatory agents and antiallergens | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-04-06 | — | — | US | disclosed |
| WO-1993002080-A1 | IMIDAZO (4,5-C) PYRIDINE DERIVATIVES AS PAF ANTAGONISTS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-02-04 | — | — | WO | disclosed |
| US-5180723-A | Hypertensives, bronchodilators, antiedemic agents | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-01-19 | — | — | US | disclosed |
| WO-1992018503-A1 | IMIDAZO (4,5-c)PYRIDO DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992003422-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| WO-1992003423-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218254-A1 | ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME | HAO2, NOTUM, FFAR2 | CYP1A2 1218/4885CYP2D6 1885/4885MAPT 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.